Abstract: Devices, systems, arid methods are provided for securing communication integrity. An. input Signal associated with a user using a remote connection to access a client server can be received. The input signal may identify an. input received via an interface. An. integrity module can be executed to generate an integrity certificate using the input signal, a secret key, and a sequential identifier corresponding to the input The integrity certificate can be generated for use during a verification process associated with the input signal. The integrity certificate and the input signal can be transmitted to the client server using one or more channels. The client server can forward the integrity certificate and the input signal to a verification server configured to validate the integrity certificate.

Abstract: In some embodiments, the systems and methods of the disclosure can provide high-throughput, programmable, and fully automatized tissue and/or cell culture and analysis platforms. In some embodiments, a culture analysis system may include a culture device that includes a cover configured to be secured to a main body, which may include one or more chambers. The cover may include one or more regions that overlaps with the one or more chambers of the main body when the cover is secured to a main body so that each region corresponds to a chamber of the main body. The cover may also include a fluidic pathway disposed in each region and configured be in fluidic communication with a corresponding chamber. Each fluidic pathway may include a fluid inlet and a fluid outlet disposed in each region. The cover may also include an optical pathway disposed in each region for the corresponding chamber.

Abstract: This disclosure relates to deodorizing compositions, ostomy devices, and uses thereof. In certain embodiments, the disclosure contemplates a deodorizer comprising a combination of citric acid and a citric acid salt, cocamidopropyl betaine, zinc ricinoleate, and optionally comprising a preservative such as a paraben. In certain embodiments, the deodorizing composition is contained loaded in a hydrogel or hydrophilic polyurethane. In further embodiments, the loaded hydrogel or hydrophilic polyurethane is placed in an ostomy device.

Abstract: This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections, such as Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infection with the disclosed compounds.

Abstract: This disclosure relates to antibodies and antigen binding fragments that specifically bind Ebola virus particles. In certain embodiments, the antibodies and fragments are capable of treating or preventing an Ebola viral infection. In certain embodiments, the antibodies and antigen binding fragments are also contemplated for diagnostic methods and compositions related thereto.

Abstract: This disclosure relates to compositions and uses of caged proteins substituted with a photon decomposing chemical structure wherein the photon decomposing chemical structure is substituted through a linking group to a hydrophilic polymer. In certain embodiments, the caged protein is a proteinaceous agent such as an anticancer agent, cytokine, interleukin, fragment, or fusion thereof.

Abstract: The systems, devices, and methods provide agents that implement self-organized partitioning with the connectivity recovery through self-healing using local information. A method may include determining, by a wireless device, one or more metrics for each agent and/or for each partition of the one or more other agents using internal and neighboring state information from information with respect to validity and/or a quality of a connection by an evaluating agent of the wireless device to each partition based on an agent type of the evaluating agent. The agent type may include a first agent and a second agent. The method may further include determining, by the first wireless device, one or more agent operations to be deployed by a wireless interface of the first wireless device with respect to the first agent or the second agent, based on the one or more metrics and the agent type.

Abstract: This disclosure relates to pyrazoline dihydroquinolone derivatives, pharmaceutical compositions, and uses. In certain embodiments, the compounds are selective NMDA receptor inhibitors and are useful in therapeutic methods related thereto. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising a compound of the following formula: or salts, esters, or prodrugs thereof, as provided herein.

Abstract: Methods and systems are provided to prevent pathological overfitting in training autoencoder networks, by forcing the network to only model structure that is shared between different data variables and to enable an automatic search of hyperparameters in training autoencoder networks, resulting in automated discovery of optimally-trained models. The method may include training a neural network. The training may include applying a first binary mask to the set of training data to determine the training input data. The training may include processing the training input data by the neural network to produce network output data. The training may include determining one or more updates of the parameters based on a comparison of at least a portion of the network output data and a corresponding portion of the training data. The portion of the network output data and the corresponding portion of the training input data being inverts.

Abstract: The disclosure relates to a device that is configured to be implanted on the native leaflet of a heart valve to increase its length and/or thickness and thereby to improve the valve function and reduce regurgitation. The device may include a leaflet section. The leaflet section may include a central member. The central member may include a first portion, a second portion that opposes the first portion, and a base portion disposed between the first portion and the second portion. The first section may extend from the first portion and the second section may extend from the second portion. The device may include one or more engaging members extending from the central member at an angle with respect to the first section and the second section. The second section may be larger than the first section. The leaflet section may define a three-dimensional region or a bulge.

Abstract: The present invention relates to methods, treatment regimens, uses, kits and therapies for prevention of graft rejection in solid organ transplantation, particularly solid organ xenotransplantation, by administering an anti-CD40 antibody or a combination of an anti-CD40 antibody and an anti-C5 antibody.

Abstract: It is disclosed herein that ssAAV and scAAV vectors of the same serotype administered by injection into the cerebrospinal fluid (CSF) via the intracerebroventricular (ICV) or intrathecal (cisternal or lumbar) route exhibit different cellular tropisms in the central nervous system. Thus, a subject can be treated by injection into the CSF of ssAAV or scAAV vector encoding a therapeutic protein, such as an ssAAV9 or scAAV9 vector. The therapeutic protein can be targeted to specific cells using these vectors. In some embodiments, scAAV9 is utilized to achieve superior transduction in the hippocampus, cerebellum and cerebral cortex where both neurons, particularly Purkinje neurons, and glial cells (such as astrocytes) are transduced. In other embodiments, ssAAV9 is utilized to minimize transduction of astrocytes. In further embodiments, an immunosuppressive agent is also administered to the subject.

Abstract: This disclosure relates to compounds according to Formula (I), salts, prodrugs and pharmaceutical formulation comprising the compound are provided herein for the treatment of CXCR4 and CCR5 related conditions. The conditions may include viral infections, abnormal cellular proliferation, retinal degeneration and inflammatory diseases, or the compounds may be used as immunostimulants or immunosuppressants. Furthermore, the compounds may be used in combination with another active ingredient selected from an antiviral agent or chemotherapeutic agent.

Abstract: In some embodiments, the systems and methods of the disclosure can efficiently and accurately classify neurodegenerative disorder(s) and/or movement disorder(s) of a subject (e.g., a patient) using at least quantitative features associated with one or more regions of interest determined from one or more sets of image data of the subject's brain. The method may include processing one or more sets of MRI image data of the subject's brain to extract one or more quantitative features for one or more regions. The one or more quantitative features may include a first quantitative and a second quantitative feature. The method may further include classifying at least the one or more quantitative features into one or more classes associated with neurodegenerative dementia disorder, neurodegenerative movement disorder, non-neurodegenerative movement disorder and/or heathy control. The method may include generating a report including a classification of at least the one or more quantitative features.

Abstract: The devices and systems can allow for safe and cost-effective administration intravenous medication, for example, in psychiatric settings by mitigating ligature, disassembly, and weaponization risks associated with intravenous administration. The system may include a fluid connection device. The fluid connection device may include an internal conduit configured to deliver a medical fluid and a housing disposed in which the internal conduit is disposed. The housing may include a first rigid segment and a second rigid segment spaced from the first rigid segment. The housing may also include a first joint segment disposed between the first rigid segment and the second rigid segment and configured to bend to the predetermined bending angle with respect to the first rigid segment.

Abstract: Compounds, compositions and methods for preventing, treating or curing a coronavirus, picornavirus, and/or hepeviridae virus infection in human subjects or other animal hosts. Specific viruses that can be treated include enteroviruses. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1 (OC43), and SARS-CoV-2. In another embodiment, the methods are used to treat a patient co-infected with two or more of these viruses, or a combination of one or more of these viruses and norovirus.

Abstract: This disclosure relates to collagen-like polypeptides and materials containing the same and uses in biomedical applications. In certain embodiments, this disclosure contemplates that collagen-like polypeptides and materials containing the same are functionalized with proteins or small molecules to create useful scaffolds for drug delivery or testing. In certain embodiments, collagen-like polypeptides and materials containing the same are used in cardiac patches, cosmetic surgery, bone grafts, tissue regeneration, and wound healing.

Abstract: Phosphate prodrugs of cannabinoids are disclosed herein as are pharmaceutical compositions comprising one or more of the same. Such compounds and compositions are useful for the treatment of diseases, disorders, and/or conditions, including neurological disorders and neuropathic pain.

Abstract: An exemplary embodiment of the present disclosure provides an MRI-compatible robot comprising one or more fiducial markers, a first planar stage comprising a first joint configured to receive a surgical tool and a first mechanism configured to move the surgical tool, a second planar stage comprising a second joint configured to receive the surgical tool and a second mechanism configured to move the surgical tool, and wherein the second planar stage is generally parallel with the first planar stage.